Perrier L, Bourrié M, Marti E, Tronquet C, Massé D, Berger Y, Magdalou J, Fabre G
Sanofi Recherche, Metabolism and Pharmacokinetic Department, Montpellier, France.
J Pharmacol Exp Ther. 1994 Oct;271(1):91-9.
The glucuronidation of the AT1 nonpeptide angiotensin II receptor antagonist, SR 47436 (BMS 186295), was investigated in hepatic microsomes prepared from various species, i.e., Sprague-Dawley rat, Cynomolgus monkey and Caucasian humans. The drug was found to undergo N-glucuronidation on the tetrazole moiety as confirmed by its hydrolysis by beta-glucuronidase, its associated radioactivity when UDP-[U-14C]glucuronic acid was used as substrate and by different techniques such as high-performance liquid chromatography-mass spectrometry and nuclear magnetic resonance. Glucuronide formation was optimal at pH 5.0 along with a "0.2 mg of Brij 58 per mg of protein" ratio, regardless of the investigated species. Cynomolgus monkey microsomes glucuronidated SR 47436 (BMS 186295) to the greatest extent, with a relative catalytic efficiency 11.0- and 2.6-fold higher than that observed in rat and human, respectively. SR 47436 (BMS 186295) glucuronidation followed Michaelis-Menten kinetics. Bilirubin:UDP-glucuronosyltransferase isoform was not involved, inasmuch as bilirubin did not affect its glucuronidation, 7,7,7-triphenylheptanoic acid was a noncompetitive inhibitor and glucuronidation was only decreased 2-fold in Gunn rats. SR 47436 (BMS 186295) glucuronidation was enhanced markedly after treatment of rats with dexamethasone (Vmax/Km = 71.5 vs. 2.6 in untreated animals). Among the drugs used which undergo phenolic, carboxylic acid, alcohol or tertiary amine glucuronidation, only monodigitoxigenin-monodigitoxoside, flurbiprofen, naproxen, testosterone and estrone inhibited SR 47436 (BMS 186295) glucoronidation in a noncompetitive manner. These data suggest that SR 47436 (BMS 186295) was glucuronidated by a highly dexamethasone-inducible UDP-glucuronosyltransferase isoform(s), different from that involved in the glucuronidation of monodigitoxigenin-monodigitoxoside.
在从不同物种(即斯普拉格 - 道利大鼠、食蟹猴和高加索人)制备的肝微粒体中,研究了AT1非肽类血管紧张素II受体拮抗剂SR 47436(BMS 186295)的葡萄糖醛酸化作用。通过β - 葡萄糖醛酸酶水解、以UDP - [U - 14C]葡萄糖醛酸为底物时的相关放射性以及高效液相色谱 - 质谱和核磁共振等不同技术证实,该药物在四唑部分发生了N - 葡萄糖醛酸化。无论所研究的物种如何,在pH 5.0以及“每毫克蛋白质0.2毫克Brij 58”的比例下,葡萄糖醛酸苷的形成最为理想。食蟹猴微粒体对SR 47436(BMS 186295)的葡萄糖醛酸化程度最高,其相对催化效率分别比在大鼠和人类中观察到的高11.0倍和2.6倍。SR 47436(BMS 186295)的葡萄糖醛酸化遵循米氏动力学。胆红素:UDP - 葡萄糖醛酸基转移酶同工型未参与其中,因为胆红素不影响其葡萄糖醛酸化,7,7,7 - 三苯基庚酸是一种非竞争性抑制剂,并且在冈恩大鼠中葡萄糖醛酸化仅降低了2倍。用 dexamethasone 处理大鼠后,SR 47436(BMS 186295)的葡萄糖醛酸化显著增强(Vmax/Km = 71.5,而未处理动物中为2.6)。在所使用的经历酚类、羧酸、醇或叔胺葡萄糖醛酸化的药物中,只有洋地黄毒苷元 - 洋地黄毒苷、氟比洛芬、萘普生、睾酮和雌酮以非竞争性方式抑制SR 47436(BMS 186295)的葡萄糖醛酸化。这些数据表明,SR 47436(BMS 186295)由一种高度地塞米松诱导的UDP - 葡萄糖醛酸基转移酶同工型进行葡萄糖醛酸化,这与参与洋地黄毒苷元 - 洋地黄毒苷葡萄糖醛酸化的同工型不同。